NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

Company Overview

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS. PrimeC has received regulatory designations intended to support its development for ALS, although it remains an investigational product and is not approved for commercial use.

The company was founded in 2017 and is led by Chief Executive Officer Alon Ben-Noon. NeuroSense’s development strategy centers on combination therapies and proprietary formulations intended to address the complex, multi-factorial nature of neurodegenerative diseases.

Key Stats

• Today's Range: $6.93 to $7.40
• 50-Day Range: $6.35 to $14.00
• 52-Week Range: $5.00 to $26.64
• Volume: 8,880 shs
• Average Volume: 25,171 shs
• Market Capitalization: $14.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $170.00
• Consensus Rating: Moderate Buy

NeuroSense Therapeutics Stock Analysis - MarketRank™

NeuroSense Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 591st out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NeuroSense Therapeutics has a consensus price target of $170.00, representing about 2,197.3% upside from its current price of $7.40.

Amount of Analyst Coverage

NeuroSense Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($7.60) to ($13.50) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.78% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 91.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroSense Therapeutics does not currently pay a dividend.

Dividend Growth

NeuroSense Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.04% of the stock of NeuroSense Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 4/07/2025
• Today: 9/24/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NRSN
• CIK: 1875091
• Web: www.neurosense-tx.com
• Phone: 972-9799-6183
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroSense Therapeutics: $170.00
• High Price Target: $280.00
• Low Price Target: $60.00
• Potential Upside/Downside: +2,197.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.96) per share
• Price / Book: -7.71

Miscellaneous

• Outstanding Shares: 1,900,000
• Free Float: 1,377,000
• Market Cap: $14.06 million
• Optionable: Not Optionable
• Beta: 1.60